A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa. (RECHARGE-1)
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Hidradenitis Suppurativa, this trial is actively recruiting participants. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
First recorded
Jan 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Almada, Portugal , Anaheim, United States , Ancona, Italy , Badalona, Spain , Barcelona, Spain , Barranquilla, Colombia , Basel, Switzerland , Beijing, China , Bellaire, United States and 127 more locations